Health & Life Sciences

Saudi Arabia Health & Life Sciences

The health care sector in Saudi Arabia receives an average of 16.5% of the government’s annual budget, reflecting its importance to socio-economic development. The Covid-19 pandemic placed significant pressure on health care systems worldwide, yet the intensified throughput allowed governments to identify weaknesses in their health services and supply chains. Saudi Arabia’s substantial sovereign reserves have seen it emerge from the worst of the pandemic in a strong position to remedy the vulnerabilities exposed by the unprecedented events of 2020-22. Moving forwards, the government plans to increase efforts to create an integrated, high-quality, value-based health care system. Public-private partnerships are targeted at strengthen specific areas of health care infrastructure, while investment in research and development capacity is set to increase.

This chapter contains an interview with Hisham bin Saad Aljadhey, CEO, Saudi Food and Drug Authority; and Fahad Al Shebel, CEO, the National Unified Procurement.

Cover of The Report: Saudi Arabia 2022

The Report

This chapter is from the Saudi Arabia 2022 report. Explore other chapters from this report.

Interviews & Viewpoints

Sketch of Hisham bin Saad Aljadhey, CEO, Saudi Food and Drug Authority (SFDA)
Hisham bin Saad Aljadhey, CEO, Saudi Food and Drug Authority (SFDA): Interview

Covid-19 Economic Impact Assessments

Stay updated on how some of the world’s most promising markets are being affected by the Covid-19 pandemic, and what actions governments and private businesses are taking to mitigate challenges and ensure their long-term growth story continues.

Register now and also receive a complimentary 2-month licence to the OBG Research Terminal.

Register Here×

Product successfully added to shopping cart